Most Loved Luxury European Accessory Brands

The NetBase 2018 Europe Luxury Accessories Social Sentiment Report is out. It reveals the most – and least – loved luxury accessories brands, highlights the effects of sentiment on social media channels, and how it this affects perception in the European luxury market.
For European luxury brands, customer experience is crucial. Their audience’s standards are exacting, and love lost may be forever. Luxury accessories aren’t merely flourishes to a big picture fashion ensemble. Collectively, they represent 62 percent of the European 87 billion euro personal luxury goods market.
Paige Leidig, chief marketing officer at NetBase, said: 'Sentiment tells brands and marketers everything about the customers you hope to reach, what they want from you, what they want from competitors, and how much they want it. Luxury brands have a high sentiment on social media, so it's vital to understand how they can differentiate themselves and drive positive customer passion.'
Social media data for the 39 top European luxury accessories brands by revenue captured customer emotions from positive or negative, with scores from -100 to +100. The scores ranged widely, even with these successful names:
1. Louis Vuitton—82%
2. Chanel—73%
3. Gucci—54%
4. Prada—88%
5. Bottega Veneta—89%
6. Yves Saint Laurent—83%
7. Balenciaga—73%
8. Brioni—59%
9. Sergio Rossi—82%
10. Pomellato—99%
Pomellato is the most adored with 99 percent, but there’s lots of love for Van Cleef & Arpels with 96 percent, and both Acqua di Parma and John Lobb, with 95 percent. On the lower end of the scale, Gucci with 54 percent needs to explore what’s driving that low score
  
Top 10 European Luxury Accessories Brands on Social Media
 
If ranked by sentiment, the list of top 10 brands looks like this: 
   
1. Pomellato
2. Van Cleef & Arpels
3. Jaeger-LeCoultre
4. Acqua di Parma
5. John Lobb
6. Vancheron Constantin
7. Emilio Pucci
8. Chopard
9. Bottega Veneta
10. Girard-Perregaux

Comments

Post a Comment

Popular posts from this blog

Pepsi Buys Rockstar

Pepsi buys Rockstar .     P epsiCo buys Rockstar Energy Beverages for $3.85 billion.     Founded in 2001, Rockstar is drinks designed for people leading an active lifestyle. Available in 20 flavors at convenience and grocery stores in 30 countries. Distributed by PepsiCo in North America since 2009. Supporting the Rockstar lifestyle across the globe through action sports, motorsports, and live music. Pepsi's energy portfolio also includes Kickstart , GameFuel, and Amp Energy.     The deal reflects the shift from reliance on sales of sugary, fizzy drinks toward options ranging from tea and coffee to still and sparkling water varieties, which appeal to health-conscious and younger consumers. Neither PepsiCo nor Coca-Cola owns a major brand in the energy drinks category, which is forecast to grow to more than $80 billion over the next five years and is now dominated by Red Bull.     2 00 countries and territories around the world enjoy ...
Read more

Compass Buys Marucci

Compass buys Marucci.     Compass Diversified Holdings buys Marucci Sports for $200 million.     Marucci Sports was founded in 2009 by Kurt Ainsworth, a retired pitcher for the San Francisco Giants and Baltimore Orioles, Joe Lawrence, a former second baseman for the Toronto Blue Jays, and Reed Dickens, a former White House Assistant Press Secretary under George W. Bush.     Marucci ’s first buy was Marucci Bat Company, launched out of a backyard shed in 2004. Ainsworth then led the buyout of an Amish-run Pennsylvania wood mill in 2008. This solidified Marucci's superior wood supply, and it still supplies all Marucci's wood today. In 2017 Marucci bought Victus , a baseball equipment maker known for its edgy designs and big attitude.     With vertically cohesive wood bat production, a global supplier group, and a client base of MVPs and World Series winners, Marucci and Victus are the top two bats among Big League players. T...
Read more

Gilead Buys Forty Seven

Gilead buys Forty Seven.     Gilead Sciences buys Forty Seven for $4.9 billion.     Forty Seven is a clinical-stage immuno-oncology firm developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on tech licensed from Stanford. Forty Seven’s lead program, magrolimab , is a monoclonal antibody against the CD47 receptor, a ‘don’t eat me’ signal that cancer cells commandeer to avoid being ingested by macrophages. Evaluated ant ibodies are in many clinical studies of patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. These assets complement the cell therapy franchise Gilead added with its 2017 buy of Kite Pharma .     Beyond magrolimab , Forty Seven is fixing to advance two more compounds into clinical testing. Developing FSI-174, an anti-cKIT antibody, in combination with magrolimab creates a novel, all-antibody conditioning regimen to address ...
Read more